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Structured Abstract 
Objectives: To examine the association between dual-antiplatelet therapy (DAPT) cessation 
and cardiovascular risk after percutaneous coronary intervention (PCI) in relation to age. 
 
Background: Examination of outcomes by age after PCI is relevant given the aging population. 
 
Methods: Two-year clinical outcomes, incidence and effect of DAPT cessation on outcomes 
were compared by ages ≤55, 56-74, and ≥75 years from the PARIS (Patterns of Non-
Adherence to Antiplatelet Regimens in Stented Patients) registry. DAPT cessation included 
physician- recommended discontinuation, interruption for surgery, and disruption (from non-
compliance or bleeding). Clinical endpoints were major adverse cardiac events (MACE) 
(composite of cardiac death, definite or probable stent thrombosis, spontaneous myocardial 
infarction, or clinically indicated target lesion revascularization), a secondary restrictive 
definition of MACE (MACE2) excluding target lesion revascularization, and bleeding. 
 
Results: A total of 1,192 (24%) patients were ≤55 years, 2,869 (57%) were 56-74 years, and 
957 (19%) were ≥75 years. Patients ≥75 years had higher DAPT cessation rates and increased 
risk of MACE2, death, cardiac death, and bleeding compared to younger patients. 
Discontinuation and interruption were not associated with increased cardiovascular risk across 
age groups, whereas disruption was associated with increased risk for MACE and MACE2 in 
younger patients, but not in patients ≥75 years (p-for-trend <0.05). 
 
Conclusion: Non-adherence and outcomes vary by age with patients ≥75 years having the 
highest DAPT cessation rates. We observed no association between outcomes and DAPT 
cessation in patients ≥75 years, whereas discontinuation was associated with lower MACE 
rates and disruption with increased MACE rates in patients <75 years. 
 
 
Keywords: Dual antiplatelet therapy, percutaneous coronary intervention, age 
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Condensed Abstract 
Two-year clinical outcomes, incidence of DAPT cessation, and effect of DAPT cessation on 
outcomes were compared by ages ≤55, 56-74, and ≥75 years from the PARIS (Patterns of 
Non- Adherence to Antiplatelet Regimens in Stented Patients) registry. DAPT cessation and 
incidence of cardiovascular events significantly varied by age with patients ≥75 years having 
the highest rates of DAPT cessation. Discontinuation and interruption were not associated 
with increased cardiovascular risk across age groups, whereas risk after disruption attenuated 
in older versus younger individuals. 
 
 
Abbreviations 
ACS= acute coronary 
syndrome(s) CI= confidence 
interval 
DAPT= dual-antiplatelet 
therapy DES= drug-eluting 
stent(s) 
HR= hazard ratio 
MACE= major adverse cardiac event(s) 
MI= myocardial infarction 
PCI= percutaneous coronary intervention 
ST= stent thrombosis 
TLR= target lesion revascularization 
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Introduction 
 
More than 650,000 patients are treated annually with percutaneous coronary 
intervention (PCI) in the United States alone (1). As the average life expectancy of the 
population continues to rise, an increasing number of PCI patients are ≥75 years old (2,3). 
Dual antiplatelet therapy (DAPT) for ≥6 months with aspirin and a P2Y12 inhibitor is the 
standard therapy of care for patients after PCI in the absence of indications for oral 
anticoagulation, whereas a shortened DAPT duration of 3 months can be considered in 
patients with high bleeding risk features according to ACC/AHA guidelines(4). Elderly 
patients are at greater risk of both ischemic and bleeding complications after PCI compared to 
younger patients (5,6). Given the increasing proportion of elderly patients, understanding 
patient outcomes by age is relevant. Furthermore, optimal duration of DAPT and net benefit 
of balancing ischemic and bleeding events warrants systemic investigation with regard to age 
(7). 
Medication adherence to DAPT after PCI is important to optimize clinical 
outcomes (8,9). Variability in medication adherence in elderly patients has been associated 
with education level, dosing frequency, explanation of medication, and health-related 
problems (10-12). Given that premature DAPT cessation is associated with an increased risk 
of stent thrombosis (ST), myocardial infarction (MI), or death, it is pertinent to understand 
the effect of DAPT cessations on outcomes with respect to age (13). 
To investigate the impact of age on modes of DAPT cessation and its association 
with major adverse cardiovascular events (MACE), the PARIS (Patterns of Non-
Adherence to Antiplatelet Regimens in Stented Patients) registry was analyzed. 
Methods 
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Study design and population 
PARIS was a prospective, international, multicenter, observational study of all-comer 
PCI patients treated with DAPT to assess different modes of DAPT cessation and their 
association with subsequent adverse cardiovascular events (13). The different modes of DAPT 
cessation (discontinuation, interruption, and disruption) were assessed in association with clinical 
events and findings from these results were published previously (13). In this subanalysis, we 
studied baseline characteristics, procedural characteristics, medication, and clinical outcomes 
among three different age groups (≤55, 56-74, ≥75 years). Furthermore, we examined the 
incidence of DAPT cessation mode in each age group, and compared risk of clinical outcomes 
between uninterrupted DAPT therapy and any DAPT cessations across age groups. 
Clinical Endpoint Definitions 
 
In the present analysis, major adverse cardiac events (MACE) were defined as the 
composite of cardiac death, definite or probable ST, spontaneous MI, or clinically indicated 
target lesion revascularization (TLR) (13). A secondary restrictive definition of MACE 
(MACE2) included cardiac death, definite or probable ST, and spontaneous MI. Death and ST 
were classified as specified by Academic Research Consortium (ARC) criteria (14). TLR was 
defined as any repeat percutaneous or surgical intervention of the target lesion and further 
classified as clinically indicated or not clinically indicated. Spontaneous MI was defined as the 
presence of clinical or electrocardiographic changes consistent with myocardial ischemia in the 
setting of increased cardiac biomarkers above the upper limit of normal (15). Bleeding was 
classified using the Bleeding Academic Research Consortium (BARC) criteria (16). A bleeding 
event, unless otherwise specified, was defined as one that met criteria for BARC type 
≥3. In addition to the BARC criteria, all bleeding events were also adjudicated using the TIMI 
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(Thrombolysis In Myocardial Infarction) and ACUITY (Acuity Catheterization and Urgent 
Intervention Triage Strategy) definitions (17,18). The modes of cessations were classified 
according to PARIS definitions as discontinuation, interruption, or disruption. Discontinuation 
included physician-directed and recommended withdrawal of the antiplatelet agent. Interruption 
was defined as temporary cessation of the antiplatelet agent due to surgery, but reinstituting 
DAPT within 14 days. Lastly, disruption was defined to include physician-recommended 
antiplatelet cessation due to bleeding or non-physician guided non-compliance. These DAPT 
classifications were not mutually exclusive, as patients could experience more than one mode of 
cessation during their 2-year follow-up period. All DAPT cessations and clinical endpoints were 
adjudicated by an external committee. DAPT cessations were adjudicated according to the 
following hierarchical order: disruption was prioritized over interruption, which in turn was 
prioritized over recommended discontinuation. 
Statistical Analysis 
 
Categorical variables are shown as frequencies and percentages and were compared 
between groups using chi-square tests. Continuous variables are expressed as mean ± SD and 
were compared using one-way ANOVA. The cumulative incidence rates for DAPT cessation 
were calculated using Kaplan-Meier estimates of time to the first cessation and were 
compared between groups using a Log-Rank test. Incidence rates for DAPT cessation were 
also represented by locally weighted regressions over continuous age (19,20). Risk for 
outcomes due to different modes of DAPT cessation was examined using a Cox regression 
analysis with DAPT cessation as a time-updated categorical variable, using uninterrupted 
DAPT over 2 years of age ≤55 years as a common reference (13). A test for trend was 
performed across age groups and mode of cessation on risk for outcomes. A test for 
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interaction was also performed for each age group using uninterrupted DAPT as the reference 
group. We presented results as hazard ratios (HRs) and 95% confidence interval (CI). We 
adjusted for the following baseline covariates: sex, diabetes, location (USA vs. Europe), stent 
type (bare metal stent vs. first-generation drug-eluting stent [DES] vs. second-generation 
DES), and the number of stents implanted. Statistical analyses were performed with Stata 
version 15.1 (StataCorp, College Station, Texas). A p-value of <0.05 was considered 
statistically significant.  
Results 
Baseline Characteristics 
 
Of the 5,018 patients in the final study population of the PARIS registry, 1,192 were 
≤55 years (24%), 2,869 were 56-74 years (57%), and 957 were ≥75 years (19%). Given that 
follow-up was fixed at 2 years, the median follow-up duration was 730 days with 9% of 
patients lost prior to the 2-year study visit. Table 1 shows the baseline characteristics of 
patients of the PARIS registry who continued DAPT for 2 years according to age group. 
Patients ≤55 years more often were current smokers, more often had a family history of 
coronary artery disease (CAD), had a higher body mass index (BMI), and more often 
presented with acute coronary syndrome (ACS) upon admission compared to the older age 
groups. Patients 56- 74 years were more often diabetic, and presented more frequently with 
silent ischemia compared to patients ≤55 and ≥75 years. Lastly, patients ≥75 years were more 
frequently female, more often had an ischemic event history, and were more likely to have 
presented with stable angina at time of admission compared to younger age groups. 
Procedural Characteristics and Medication 
 
At time of admission, patients ≥75 years were more often treated for left main CAD, 
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whereas patients ≤55 years were more often treated for a thrombotic lesion. Furthermore, 
patients ≤55 years more often received glycoprotein IIb/IIIa inhibitors during PCI. Patients 
≥75 years more often received bare metal stents during PCI compared to the other age 
groups. Overall, patients most frequently received a second-generation DES, with patients 
56-74 years more frequently receiving a second-generation DES compared to the other age 
groups. At discharge, younger patients were more frequently prescribed prasugrel compared 
to older age groups, whereas clopidogrel, warfarin, and a proton pump inhibitor were more 
often prescribed with increasing age (Table 2). 
DAPT Cessation 
 
Of the different modes of DAPT cessation, the cumulative incidence at 2 years for 
discontinuation (p<0.0001) and interruption (p=0.003) increased significantly with age 
(Figure 1). The incidence of disruption was highest among patients ≥75 years, although there 
was a higher incidence in patients ≤55 years compared to patients 56-74 years (18.1 % vs. 
14.3% vs. 13.0%; p=0.0003, Figure 1). Discontinuation was the most frequent mode of 
cessation, and disruption was more frequent than interruption (Figure 1). Using age as a 
continuous variable, the frequency of discontinuation increased until 80 years, and then 
decreased in frequency as age increased beyond 80 years. Contrastingly, the frequency of 
disruption decreased with increasing age until 60 years, and then increased with age from 60-
90 years. Interruption increased with age, but plateaued after 60 years (Figure 2). 
Outcomes 
 
The incidence of death, cardiac death, BARC major bleeding, TIMI major bleeding, 
and MACE2 at 2 years was significantly higher in patients ≥75 years, and increased with 
increasing age (Table 3). When adjusted for sex, diabetes, location (USA vs. Europe), stent 
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type (bare metal stent vs. first-generation DES vs. second-generation DES), and the number of 
stents implanted, patients ≥75 years had higher rates of death, cardiac death, BARC major 
bleeding, and MACE2 (p<0.0001, p=0.003, p<0.0001, p=0.04 respectively) (Table 4). 
Contrarily, the adjusted incidence of clinically indicated TLR was lower in patients ≥75 years 
compared to younger patients (p=0.02). 
Age-associated Risks of DAPT Cessation 
 
Figure 3 shows the time-adjusted risk of adverse events through comparison of 
different DAPT cessation modes to uninterrupted DAPT. Physician-recommended 
discontinuation was associated with lower rates of adverse events in younger patients and was 
not associated with an increased risk for MACE in patients ≥75 years (ptrend=0.01). 
Discontinuation was also not associated with increased risk for MACE2 without a significant 
trend according to age groups (ptrend=0.51). The risk for MACE or MACE2 after interruption 
was not modified by age (MACE ptrend=0.29; MACE2 ptrend=0.97). Contrastingly, disruption 
of DAPT was associated with increased risk of MACE and MACE2 in patients ages ≤55 
years and 56-74 years, but cardiovascular risk was attenuated in patients ≥75 years (MACE 
ptrend=0.03; MACE2 ptrend<0.0001). The test for interaction between DAPT cessation and 
cardiovascular risk in each age group was not significant for MACE or MACE2. 
Discussion 
Our findings show that the incidence of each mode of DAPT cessation differed 
significantly with age. Whereas older age was associated with a higher incidence of DAPT 
cessation due to discontinuation or interruption, disruption displayed a bimodal pattern occurring 
more frequently in both younger and older patients. Furthermore, age ≥75 years was associated 
with significantly higher adverse event rates compared to younger patients. Finally, we observed 
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a significant trend for risk of MACE and MACE2 among age groups after DAPT disruption, 
indicating an association with increased cardiovascular risk in the younger patient groups, but 
not in patients ≥75 years.  
Given the ongoing debate on the optimal duration of DAPT, the consideration of 
potential beneficial effects of long-term DAPT must be compared to the increased risk of 
bleeding and subsequent increased risk of mortality (21-24). Many randomized trials comparing 
a shortened duration to a prolonged duration of DAPT showed shortened DAPT duration was 
associated with lower risk of bleeding and lower mortality with the increased use of second 
generation DES (23-26). The results from the current analysis show higher incidences of all 
modes of DAPT cessation in age ≥75 years compared to other age groups. Furthermore, the 
highest incidences of adverse events were among the oldest age group. Such findings are 
expected given that older patient populations are typically burdened with more comorbidity 
(3,6). Physicians treating these elderly patients likely considered the greater risk for the harmful 
effects of bleeding from DAPT compared to the protective effects from thrombotic events in 
duration of DAPT. The current analysis suggests that age is not a modifier of risk of adverse 
cardiovascular events after discontinuation or interruption. Discontinuation in particular was 
associated with lower rates of MACE in younger patient groups and was not associated with 
increased risk in patients ≥75 years. Such findings support the use of physician-recommended 
discontinuation and interruption as safe clinical practices. 
The incidence of disruption differed from those of interruption and discontinuation 
with respect to age. Whereas the incidence of discontinuation and interruption increased with 
increasing age, disruption was highest in the elderly group, but also higher in the youngest 
patient population compared to ages 56-74 years. Although a relatively high rate of disruption 
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in patients ≥75 years can be expected as a result of an expected higher rate of bleeding, the 
seemingly paradoxical increase of noncompliance in younger patients is consistent with the 
Fixed-Dose Combination Drug for Secondary Cardiovascular Prevention (FOCUS) study 
(27). Medication noncompliance is a common and clinically important problem, yet 
complicated by its often multifaceted nature (11). Many factors that affect medication 
adherence include socio-economic, health system-related, condition-related, 
therapy/medication-related, and patient- related factors (11,12) . FOCUS showed that age <50 
years, as well as depression, lack of social support, and complexity of treatment contributed 
independently to non-compliance (27).  Moreover, in TRANSLATE-ACS (Treatment With 
Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns 
and Events After Acute Coronary Syndrome) DAPT disruption was associated with younger 
patient age and socio-economic factors such as lack of health insurance (28). It is difficult to 
interpret increased disruption in younger patient populations given the array of factors that 
impact medication adherence. However, one possible explanation may be that these young 
patients with early cardiovascular events differ from young people in the general population 
in such factors that impact medication adherence. 
The risk for cardiovascular events after disruption was also significantly modified 
by age group. We observed a significant trend showing an attenuation of risk after DAPT 
disruption with increasing age. The current analysis showed significantly increased rates of 
MACE and MACE2 in patients ≤55 years and 56-74 years, but not in patients ≥75 years. 
These findings suggest that the risk of adverse clinical outcomes after DAPT disruption may 
not be as severe in older patients, thereby rendering them suitable candidates for a shortened 
DAPT duration after PCI with stent implantation. Future adequately-powered clinical trials 
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should therefore be conducted to investigate the safety and efficacy of shortened DAPT 
duration in older patients.  Indeed, the efficacy and safety of potent P2Y12 inhibitors versus 
clopidogrel is not modified by age (29). In contrast, medication noncompliance and risk for 
cardiovascular events after disruption remain as major concerns when treating younger 
patients. Given that medication cost is often an important socio-economic factor that can 
affect medication adherence, ARTEMIS (The Affordability and Real-World Antiplatelet 
Treatment Effectiveness After Myocardial Infarction Study) showed an increased persistence 
with P2Y12 inhibitors when patients were provided vouchers to cover medication co-
payments (30). Furthermore, guided DAPT de-escalation strategies have been shown to 
significantly benefit younger patients in decreasing cardiovascular risk (31). Younger patients 
may therefore benefit from strategies such as co-pay reduction or DAPT de-escalation to 
improve medication adherence and lower risk for adverse clinical outcomes.   
 
Limitations 
 
This PARIS subanalysis was performed in an observational study, thus precluding causal 
inferences. DAPT cessation information collected was also self-reported, which may have 
caused potential bias. Despite the known effect on the adherence, socio-economic status and 
psychosocial parameters such as mental health were not collected. Information on bleeding 
history was also not available, although ischemic history was assessed. Additionally, the age 
group cutoff utilized did not result in an even distribution of the numbers of patients. However, 
this was done with consideration to the preference of clinical applicability, and cutoffs used in 
the Prospective Randomized Comparison of the BioFreedom Biolimus A9 Drug-Coated Stent 
versus the Gazelle Bare-Metal Stent in Patients at High Bleeding Risk (LEADERS FREE) and 
FOCUS trials (27,32). Furthermore, only 6% of patients were prescribed prasugrel although 
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≥40% of patients enrolled presented with an ACS, and ticagrelor had not yet been approved 
during the time of enrollment. Given that current guidelines recommend prasugrel and ticagrelor 
in patients presenting with ACS, our findings warrant confirmation in larger samples treated with 
potent P2Y12 inhibitors (4,21). Lastly, the low number of events reported per group of this 
subanalysis limited the power of analyses investigating associations between DAPT cessation 
and clinical outcomes, especially in patients ≥75 years. 
Conclusion 
 
Patterns of non-adherence to DAPT and incidence of cardiovascular events 
significantly vary by age with patients ≥75 years having the highest rates of DAPT cessation. 
We observed no association between clinical outcomes and DAPT cessation in patients ≥75 
years, whereas discontinuation was associated with lower MACE rates and disruption with 
increased MACE rates in patients <75 years. 
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Clinical Perspectives 
 
What’s known? Risk for cardiovascular events after DAPT cessation in PCI-treated patients 
can vary according to duration and reason for cessation. It is well known that elderly patients 
are at greater risk of both ischemic and bleeding complications after PCI compared to younger 
patients. However, patterns of DAPT cessation and subsequent risks for adverse outcomes 
according to age are unknown. 
What is new? Elderly patients had higher rates of DAPT cessation compared to younger age 
groups in the 2 years after PCI. The impact of each mode of DAPT cessation varied 
significantly by age. Discontinuation and interruption were not associated with increased 
cardiovascular risk across age groups, whereas disruption was associated with increased 
cardiovascular risk in younger patients but not in patients ≥75 years. 
What is next? Future prospective studies should be conducted to investigate the safety and 
efficacy of shortened DAPT in older patients. In younger patients, strategies should be 
developed to optimize medication adherence and mitigate risk for adverse cardiovascular 
events after disruption. Younger patients may benefit from DAPT de-escalation strategies, as 
well as strategies that account for socio-economic and patient-centered factors. 
DAPT Cessation Outcomes by Age After PCI 
 
Figure Titles and Legends 
 
Figure 1. Title: Cumulative Incidences of Mode of Dual-Antiplatelet Therapy Cessation 
Across Follow-up Time Points. Legend: (A) The cumulative incidence of any DAPT cessation 
through 2 years after PCI in patients ages ≤55 vs. ages 56-74 vs. ages ≥75 years. The 
cumulative incidence of DAPT discontinuation, interruption, and disruption are represented in 
B, C, and D, respectively. DAPT=dual-antiplatelet therapy. 
Figure 2.Title: Incidence of Dual-Antiplatelet Therapy Cessation Mode According to Age as a 
Continuous Variable. Legend: Central Figure. Incidence rates (%) at 2 years are represented by 
locally weighted regression over continuous age. 
Figure 3. Title: Adjusted Risk for Adverse Cardiovascular Events at 2 years by Dual- 
Antiplatelet Therapy Cessation Mode According to Age Group. Legend: Patients age ≤55 
years on dual-antiplatelet therapy (DAPT) were used as the reference group. All modes 
included the following variables: sex, diabetes, location (USA vs. Europe), stent type (bare 
metal stent vs. first-generation drug-eluting stent [DES] vs. second-generation DES), and the 
number of stents implanted. CI= confidence interval; DAPT= dual-antiplatelet therapy; HR= 
hazard ratio with 95% confidence interval; MACE= major adverse cardiac event(s) (cardiac 
death, myocardial infarction, clinically indicated target lesion revascularization, or definite or 
probable stent thrombosis); MACE2= major adverse cardiac event(s) 2 (cardiac death, 
myocardial infarction, or definite or probable stent thrombosis). 
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Table 1. Baseline Characteristics 
 Age ≤55 
(n=1192 
[24.0%]) 
55<Age<75 
(n=2869 
[57.0%]) 
Age ≥75 
(n=957 
[19.0%]) 
 
 
p Value 
Female 215 (18.0%) 698 (24.3%) 366 (38.2%) <0.0001 
BMI, kg/m 2 30.3 ± 6.1 29.4 ± 5.6 27.7 ± 4.8 <0.0001 
Dyslipidemia requiring medication 818 (68.6%) 2225 (77.6%) 758(79.2%) <0.0001 
Hypertension requiring medication 811 (68.0%) 2356 (82.1%) 842(88.0%) <0.0001 
Family History of CAD 483 (40.5%) 909 (31.7%) 214 (22.4%) <0.0001 
Current Smoker 458 (38.4%) 481 (16.8%) 42 (4.4%) <0.0001 
Diabetes 321 (26.9%) 1020 (35.6%) 313 (32.7%) <0.0001 
On Insulin 113 (9.5%) 341 (11.9%) 91 (9.5%) 0.46 
Education Level    <0.0001 
Less than Secondary School 128 (10.7%) 313 (10.9%) 152 (15.9%)  
Secondary School 604 (50.7%) 1395 (48.6%) 484 (50.6%)  
Tertiary University Degree 345 (28.9%) 780 (27.2%) 222 (23.2%)  
Advanced degree 88 (7.4%) 312 (10.9%) 85 (8.9%)  
Ischemic history     
Previous MI 289 (24.2%) 702 (24.5%) 223 (23.3%) 0.77 
Previous CABG 83 (7.0%) 405 (14.1%) 197 (20.6%) <0.0001 
Stroke (CVA) 18 (1.5%) 106 (3.7%) 49 (5.1%) <0.0001 
TIA 21 (1.8%) 75 (2.6%) 41 (4.3%) 0.002 
PVD 65 (5.5%) 222 (7.7%) 105 (11.0%) <0.0001 
Previous CAD (Prior PCI, CABG, or MI) 493 (41.4%) 1460 (50.9%) 536 (56.0%) <0.0001 
Cardiac status at admission     
Silent Ischemia 96 (8.1%) 336 (11.8%) 90 (9.5%) 0.001 
Stable Angina 487 (40.9%) 1454 (50.7%) 500 (52.2%) <0.0001 
Acute Coronary Syndrome 608 (51.0%) 1081 (37.7%) 367 (38.3%) <0.0001 
Values are n (%) or mean ± SD. 
BMI= body mass index; CABG= coronary artery bypass grafting; CAD= coronary artery disease 
including myocardial infarction, PCI, and CABG; CVA= cerebrovascular accident; MI= myocardial 
infarction; PCI= percutaneous coronary intervention; PVD= peripheral vascular disease; TIA= transient 
ischemic attack. 
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Table 2. Procedural Characteristics 
 Age ≤55 
(n=1192 
[24.0%]) 
55<Age<75 
(n=2869 
[57.0%]) 
Age ≥75 
(n=957 
[19.0%]) 
 
 
p Value 
PCI vessel     
Left main 22 (1.8%) 81 (2.8%) 55 (5.7%) <0.0001 
Left anterior descending 576 (48.3%) 1302 (45.4%) 446 (46.6%) 0.23 
Proximal left anterior descending 267 (22.4%) 631 (22.0%) 219 (22.9%) 0.84 
Left circumflex 340 (28.5%) 896 (31.2%) 314 (32.8%) 0.08 
Right coronary artery 429 (36.0%) 1007 (35.1%) 324 (33.9%) 0.59 
Number of vessels treated    0.03 
One 1026 (86.1%) 2479 (86.4%) 787 (82.2%)  
Two 157 (13.2%) 363 (12.7%) 158 (16.5%)  
Three 9 (0.8%) 27 (0.9%) 12 (1.3%)  
Bifurcation lesion 132 (11.1%) 340 (11.9%) 123 (12.9%) 0.45 
Chronic total occlusion 49 (4.1%) 119 (4.1%) 24 (2.5%) 0.06 
Thrombotic lesion 163 (13.7%) 207 (7.2%) 45 (4.7%) <0.0001 
Stent type     
Bare metal stent 228 (19.1%) 432 (15.1%) 224 (23.4%) <0.0001 
First-generation DES 151 (12.7%) 406 (14.2%) 117 (12.2%) 0.22 
Second-generation DES 861 (72.2%) 2137 (74.5%) 671 (70.1%) 0.02 
Number of stents implanted    0.17 
1 681 (57.1%) 1595 (55.6%) 506 (52.9%)  
2 336 (28.2%) 804 (28.0%) 275 (28.7%)  
>2 175 (14.7%) 470 (16.4%) 176 (18.4%)  
Total stent length    0.42 
≤20 mm 471 (39.5%) 1075 (37.5%) 373 (39.0%)  
>20 mm 721 (60.5%) 1794 (62.5%) 584 (61.0%)  
GP inhibitor 221 (18.5%) 391 (13.6%) 72(7.5%) <0.0001 
Discharge medication     
Aspirin 1192 (100.0%) 2869 (100.0%) 957 (100.0%)  
Thienopyridine 1192 (100.0%) 2869 (100.0%) 957 (100.0%)  
Warfarin 42 (3.5%) 163 (5.7%) 109 (11.4%) <0.0001 
Thienopyridine Type    <0.0001 
Clopidogrel 1060 (88.9%) 2641 (92.1%) 934 (97.6%)  
Prasugrel 119 (10.0%) 179 (6.2%) 16 (1.7%)  
Ticlopidine 13 (1.1%) 49 (1.7%) 7 (0.7%)  
Proton Pump Inhibitor 246 (20.6%) 679 (23.7%) 249 (26.0%) 0.012 
Values are n (%) 
 
DES= drug-eluting stent(s); GP= glycoprotein 
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Table 3. Incidence of Clinical Outcomes at 12 and 24 Months by Age 
 Age ≤55 
(n=1192 
[24.0%]) 
55<Age<75 
(n=2869 
[57.0%]) 
Age ≥75 
(n=957 
[19.0%]) 
 
 
p Value* 
Death     
12 Months 18 (1.6%) 59 (2.1%) 36 (3.8%) <0.0001 
24 Months 30 (2.7%) 115 (4.2%) 82 (8.8%) <0.0001 
Cardiac death     
12 Months 18 (1.6%) 44 (1.6%) 23 (2.4%) 0.14 
24 Months 25 (2.2%) 74 (2.7%) 49 (5.4%) <0.0001 
Probable or definite stent thrombosis     
12 Months 14 (1.2%) 36 (1.3%) 5 (0.5%) 0.18 
24 Months 19 (1.7%) 45 (1.6%) 7 (0.8%) 0.11 
Clinically indicated TLR     
12 Months 61 (5.3%) 151 (5.4%) 37 (4.0%) 0.21 
24 Months 91 (8.1%) 212 (7.7%) 53 (5.9%) 0.07 
Spontaneous MI     
12 Months 23 (2.0%) 64 (2.3%) 21 (2.3%) 0.65 
24 Months 43 (3.9%) 100 (3.6%) 37 (4.1%) 0.78 
TIMI major     
12 Months 10 (0.9%) 41 (1.5%) 19 (2.0%) 0.02 
24 Months 11 (1.0%) 59 (2.1%) 31 (3.4%) 0.0001 
BARC major (BARC ≥ 2)     
12 Months 40 (3.4%) 160 (5.7%) 90 (9.6%) <0.0001 
24 Months 56 (4.9%) 218 (7.9%) 127 (13.9%) <0.0001 
BARC major (BARC ≥ 3)     
12 Months 17 (1.5%) 79 (2.8%) 40 (4.3%)         <0.0001 
24 Months 21 (1.8%) 114 (4.1%) 61 (6.7%) <0.0001 
MACE     
12 Months 82 (7.0%) 211 (7.5%) 70 (7.4%) 0.71 
24 Months 130 (11.4%) 311 (11.2%) 117 (12.7%) 0.42 
MACE2     
12 Months 38 (3.3%) 108 (3.8%) 46 (4.9%) 0.59 
24 Months 64 (5.7%) 170 (6.1%) 81 (8.8%) 0.006 
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Values are n (%) 
 
*P-values are for a test for trend in % across age groups 
 
BARC= Bleeding Academic Research Consortium; MACE= major adverse cardiac event(s) (cardiac death, myocardial 
infarction, clinically indicated target lesion revascularization, or definite or probable stent thrombosis); MACE2= major 
adverse cardiac event(s) 2 (cardiac death, myocardial infarction, or definite or probable stent thrombosis); MI= 
myocardial infarction; TIMI=thrombolysis in myocardial infarction; TLR= target lesion revascularization. 
 
 
 
 
Table 4. Adjusted Outcomes at 24 Months by Age 
 Unadjusted Adjusted 
Event HR [CI%] p Value HR [CI%] p Value 
Death     
≤55 Ref.    
56-74 1.57 [1.05,2.34] 0.03 1.56 [1.04,2.33] 0.03 
≥75 3.40 [2.24,5.16] <.0001 2.93 [1.92,4.47] <0.0001 
Cardiac death     
≤55 Ref.    
56-74 1.21 [0.77,1.90] 0.41 1.17 [0.75,1.86] 0.48 
≥75 2.44 [1.51,3.94] 0.0003 2.11 [1.30,3.44] 0.003 
Spontaneous MI     
≤55 Ref.  Ref.  
56-74 0.95 [0.67,1.37] 0.80 0.95 [0.66,1.36] 0.79 
≥75 1.07 [0.69,1.67] 0.75 0.97[0.61,1.51] 0.88 
Clinically indicated TLR     
≤55 Ref.  Ref.  
56-74 
≥75 
0.96 [0.75,1.22] 
0.72 [0.51,1.01] 
0.73 
0.06 
0.92 [0.72,1.18] 
0.67 [0.47,0.94] 
0.53 
0.02 
Definite/probable ST     
≤55 Ref.  Ref.  
56-74 0.98 [0.57,1.67] 0.93 0.98 [0.57,1.68] 0.93 
≥75 0.46 [0.19,1.09] 0.08 0.42 [0.18,1.02] 0.06 
BARC major (BARC ≥2)     
≤55 Ref.  Ref.  
56-74 1.62 [1.21-2.17] 0.001 1.61 [1.20-2.17] 0.001 
≥75 2.94 [2.15-4.03] <0.0001 2.60 [1.89-2.17] <0.0001 
BARC major (BARC≥3)     
≤55 Ref.  Ref.  
56-74 2.24 [1.40-3.58] 0.001 2.23 [1.40-3.57] 0.001 
≥75 3.68 [2.24-6.05] <0.0001 3.21 [1.94-5.31] <0.0001 
MACE     
DAPT Cessation Outcomes by Age After PCI 
 
≤55 Ref.  Ref.  
56-74 0.98 [0.80,1.21] 0.87 0.96 [0.78,1.18] 0.70 
≥75 1.11 [0.87,1.43] 0.39 1.03 [0.78,1.32] 0.83 
MACE 2     
≤55 Ref.  Ref.  
56-74 1.09 [0.82,1.46] 0.55 1.07 [0.80,1.43] 0.63 
≥75 1.58 [1.14,2.19] 0.006 1.42 [1.02,1.98] 0.04 
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